Tocagen Inc.

University of Southern California

National Institute of Transplantation Foundation

Denovo Biopharma LLC

Christopher R Logg

Noriyuki Kasahara

Douglas J Jolly

Harry E Gruber

Omar D Perez

W French Anderson

James C Cicciarelli

Amy Lin

Amy H Lin

This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.

Retroviral vector with mini-promoter cassette

Virus vectors wherein each of the virus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a modulator for nucleic acid encoding a domain.

Vectors and methods for long-term immune evasion to prolong transplant viability

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Recombinant vectors

A kit for altering allogeneic human cells for a human recipient where the kit includes a set of lentivirus vectors where each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and where the set of lentivirus vectors includes individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch and where the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient.

Gene therapy vectors and cytosine deaminases

A method can include making one or more compositions for altering allogeneic cells of a human donor for a human recipient by identifying at least one mismatch in an HLA protein between the human donor and the human recipient; determining a consensus conserved nucleic acid sequence among nucleic acid sequences encoding a domain having the mismatch or among domains having a plurality of mismatches; and forming at least one of the one or more compositions by constructing a virus vector for expressing a sequence targeting the consensus conserved nucleic acid sequence, which when expressed in cells functions as a negative modulator for nucleic acid encoding the domain having the mismatch or the domains having the plurality of mismatches.

Vectors and methods for long-term immune evasion to prolong tranplant viability

This disclosure provides recombinant replication competent retroviral vectors having increased stability. The disclosure further relates compositions and uses of such vectors in the treatment of disease and disorders.

A recombinant replication competent retrovirus for gene deliver and gene therapy is provided. The recombinant retrovirus has a heterologous nucleic acid sequence, a sequence encoding a cell- or tissue-specific ligand or a sequence for transcriptional targeting, or a combination of both a cell- or tissue-specific ligand and a cell- or tissue-specific transcriptional targeting sequence.

Gene delivery system and methods of use

Gene delivery system and method of use

Vector compositions and methods are provided for transfecting donor cell populations and tissues for grafts, for reducing expression of mismatched proteins, thereby reducing immunogenicity of the grafted cells and tissues in a recipient subject.

Growing community of inventors

South Pasadena, CA, United States of America

Christopher R Logg